|
|
 |
| |
|
Home > Drug Companies > Barr Laboratories
Barr Laboratories
The Company is founded in 1970 in New York, Barr Laboratories was one of the first generic pharmaceutical companies in the United States. In 1972, the Company launched its first generic product and was one of the earliest producers of antibiotic products. However, the growth of the Company, and the generic pharmaceutical industry as it is known today, did not begin in earnest until more than a decade later.
The milestone that is acknowledged as the start of the modern generic pharmaceutical industry was the Drug Price Competition and Patent Restoration Act in 1984. This law, often called the Hatch Waxman Act, opened the floodgates for generic competition for pharmaceutical products, creating the modern generic pharmaceutical industry. Hatch Waxman established the criteria which has become the foundation of generic product approval.
In January 2004, the Company was reincorporated in Delaware as Barr Pharmaceuticals, Inc. Barr Laboratories, Duramed Research and Duramed Pharmaceuticals were established as subsidiaries of Barr Pharmaceuticals. The action enabled the company to take full advantage of Delaware corporate law and created a corporate structure more optimally aligned for future growth.
The Company is a Delaware holding company whose principal subsidiaries, Barr Laboratories and Duramed Pharmaceuticals develop, manufacture and market generic and proprietary pharmaceutical products, respectively. The Company’s generic products are marketed under the Barr label, and proprietary products are marketed under the Duramed label.
Barr develops and markets generic pharmaceuticals under the Barr label that are the generic equivalent of brand pharmaceuticals that no longer enjoy patent protection. The Company focuses on products that have one or more characteristics that make it difficult for other competitors to develop competing generics.
The people of Barr Pharmaceuticals are focused on developing, manufacturing and marketing quality generic and proprietary pharmaceuticals in specific therapeutic categories that generate sustainable profitability. Their confidence in their ability to achieve success is based on the skill and dedication of their employees and their commitment to excellence in science, manufacturing and customer satisfaction.
Back to Drug Companies
|
|
|
|
|
|
|
|